Lipid Nanoparticle Composition for Nucleic Acid Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Nucleic acid therapeutics face challenges such as low cell permeability and high susceptibility to degradation, particularly for RNA molecules, limiting their delivery and efficacy in therapeutic and prophylactic applications.
Innovation Solution
Development of lipid nanoparticles comprising specific lipid compounds, including cationic lipids, neutral lipids, and polymer conjugated lipids, to facilitate the delivery of nucleic acid molecules, such as antisense and messenger RNA, by forming complexes that enhance cellular uptake and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Device complexity
If nucleic acid molecules are used directly for delivery, then the delivery process is simple, but cell permeability is low and susceptibility to degradation is high
Solution Approach 1:
The patent uses composite lipid materials including ionizable lipids, neutral lipids, and PEGylated lipids to form lipid nanoparticles that encapsulate nucleic acids. This composite approach provides both protection against degradation and enhanced cell permeability while maintaining manageable formulation complexity
Solution Approach 2:
The lipid nanoparticle forms a flexible lipid bilayer shell around the nucleic acid cargo. This thin film structure protects the encapsulated nucleic acid from enzymatic degradation while allowing cellular uptake through endosomal escape mechanisms
2Reliability
If lipid nanoparticles are used to deliver nucleic acids, then cell permeability and stability are improved, but the formulation complexity increases
Solution Approach 1:
The patent optimizes specific parameters including the pKa of ionizable lipids (5.5-8.5), lipid to nucleic acid ratio (1:1 to 10:1), and nanoparticle size (50-200 nm). These parameter optimizations achieve reliable delivery while standardizing the formulation process to manage complexity
Solution Approach 2:
The patent introduces auxiliary components such as cholesterol as a structural mediator and PEGylated lipids as surface modifiers that facilitate nanoparticle formation and stabilization. These intermediaries simplify the overall formulation by performing specialized functions that enable reliable delivery
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The lipid nanoparticles improve the delivery and stability of nucleic acid molecules, overcoming permeability and degradation issues, thereby enhancing their therapeutic and prophylactic potential, including in vaccination and gene therapies.
Implementation Method 1
lipid nanoparticles comprising specific lipid compounds, including cationic lipids, neutral lipids, and polymer conjugated lipids, to facilitate the delivery of nucleic acid molecules
Implementation Method 2
forming complexes that enhance cellular uptake and stability
Data Source
Figure 1
Figure 2
AI summary
Provided herein are lipids that can be used in combination with other lipid components, such as neutral lipids, cholesterol and polymer conjugated lipids, to form lipid nanoparticles for delivery of therapeutic agents (e.g., nucleic acid molecules) for therapeutic or prophylactic purposes, including vaccination.